Skip to main content
. 2016 Jan 5;11(1):e0146259. doi: 10.1371/journal.pone.0146259

Fig 6. PKR antagonist PC1 restores a correct pro-anti-inflammatory cytokine balance in spinal cord and sciatic nerve.

Fig 6

Effect of therapeutic PC1 administrations on cytokines levels in spinal cord and sciatic nerve. IL-1β (A, C, E and G) and IL-10 (B, D, F and H) protein content and mRNA expression in spinal cord and sciatic nerve 35 days after diabetes induction with MLD-STZ, at the end of therapeutic treatment with PC1 (s.c. 150 μg/ kg, twice-daily for 14 days starting on day 21 from the first STZ injection). Cytokine protein content, evaluated by ELISA, was reported as pg cytokine/ mg total proteins (A, B, E and F). Cytokine mRNA levels, determined by Real Time PCR, were expressed in relation to GAPDH and presented as fold-increase over the levels in vehicle/CTR animals (C, D, G and H). Inset c and d: expression levels of IL-1β (inset c) and IL-10 (inset d) evaluated 56 days after STZ, corresponding to 3 weeks after last PC1 injection. Data represent mean ±SEM of 6–8 mice per group. One way ANOVA was used for statistical evaluation, followed by Tukey’s test for multiple comparisons. *p<0.05, ** p<0.01, ***p<0.001 vs vehicle; °p<0.05, °°p<0.01, °°°p<0.001 vs STZ.